Diagonal Bio

Executive Summary

Diagonal Bio is a Swedish diagnostics company developing a next-generation panviral diagnostic platform that combines accuracy, speed, and ease-of-use for point-of-care testing. Founded in 2020 and based in Stockholm, the company aims to address the need for cost-efficient, high-quality medical testing that can be deployed at the point of care, potentially replacing or augmenting traditional lab-based methods. While still in early stages with no disclosed funding or commercial products, its focus on a broad-spectrum viral detection platform positions it in the rapidly growing point-of-care diagnostics market. The company's progress will depend on achieving key technical milestones, securing regulatory approvals, and forming strategic partnerships to enable production and distribution. Given the competitive landscape and the capital-intensive nature of diagnostics development, Diagonal Bio's path to commercialization carries significant risk but also considerable upside if it can deliver on its promises of accuracy and usability.

Upcoming Catalysts (preview)

• Q4 2026Initiation of clinical trials for panviral platform40% success
• Q2 2027Regulatory submission (CE marking or FDA breakthrough designation)30% success
• Q1 2027Series A or strategic partnership announcement50% success